AMENDED AND RESTATED SUPPLY AGREEMENT dated October 24, 2018 by and betweenSupply Agreement • February 20th, 2019 • Bausch Health Companies Inc. • Pharmaceutical preparations • England and Wales
This Amended and Restated Supply Agreement (this “Agreement”), dated October 24, 2018 (the “Effective Date”), is entered into by and between ALFASIGMA S.p.A. (formerly, Alfa Wassermann S.p.A.), a società per azioni (joint stock company) duly incorporated under the laws of Italy, having its headquarters at Via Ragazzi del ̒99, 40133, Bologna, Italy (“Alfa”), on the one hand, and SALIX PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of California, United States of America, having its principal place of business at 400 Somerset Corporate Blvd., Bridgewater, NJ 08807, USA (“Salix Inc.”), VALEANT PHARMACEUTICALS IRELAND LIMITED, a corporation duly organized and existing under the laws of Ireland, having its principal place of business at 3013 Lake Drive, Citywest Business Campus, Dublin 24, D24 PPT3 Ireland (“VIRL”), and VALEANT PHARMACEUTICALS LUXEMBOURG S.à.r.l., a company duly organized and existing under the laws of Luxembourg, having its pri
AMENDMENT NUMBER TWO dated October 24, 2018 to AMENDED AND RESTATED LICENSE AGREEMENT dated August 6, 2012 by and between ALFASIGMA S.P.A. (formerly Alfa Wassermann S.P.A.) and SALIX PHARMACEUTICALS, INC., VALEANT PHARMACEUTICALS IRELAND LIMITED, and...License Agreement • February 20th, 2019 • Bausch Health Companies Inc. • Pharmaceutical preparations
AMENDMENT NUMBER TWO (this “Amendment”) dated October 24, 2018 (the “Amendment Number Two Effective Date”), to the AMENDED AND RESTATED LICENSE AGREEMENT dated August 6, 2012, as amended on September 5, 2012, by and among Alfasigma S.p.A. (formerly, Alfa Wassermann, S.P.A.), a società per azioni (joint stock company) duly incorporated under the laws of Italy (“Alfasigma”), on the one hand, and Salix Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of California, United States of America (“Salix Inc.”), Valeant Pharmaceuticals Ireland Limited, a corporation duly organized under the laws of Ireland (“VIRL”), and Valeant Pharmaceuticals Luxembourg, S.á.r.l., a company duly organized under the laws of Luxembourg (“VPL”) (collectively, Salix Inc. together with VIRL and VPL, “Salix”), on the other hand (each a “Party,” and collectively “the Parties”).
